U the brain company

In order to circumvent the ever-changing class of neuropsychiatric pathologies, we have created a neuromodulatory device that essentially massages this mind to relieve itself of unwarranted mental states and degenerative tendencies. The device is able to send multiple forms of electrical signals to target specific neural firing patterns. The user does not feel any initial changes to the stimulation but the continual practice and usage of the device eventually help rewire the brain to perform properly. In order to devise an optimal electrical stimulation, we use EEG channels to record the patient's ongoing mental states. We are also in the process of conducting fMRI studies to further our statistical analysis and therapeutic effects.

Covid-19 has exposed some of the most pressing neuropsychiatric issues that many common citizens are beginning to deal with. With a rise of necessary screen time and ever-changing social conduct, the fabric of optimal mental health is constantly challenged. In 2019 the NHIS reported negative mental health reports of about 11% of all U.S. citizens. In 2020, this number increased to 41% in respect to the culmination of events that resulted from Covid-19.

We aim to be a non pharmaceutical therapeutic device that mitigates neurodegenerative diseases and neuropsychiatric symptoms. Our pulse protocol is derived from various neural engineering literature sources. We use transcranial pulsed current stimulation technology to target both superficial and deep circuits of the brain.  Our optimized electrical stimulation is projected to be unique to the user's conduction as it is capable of both reading and altering neural states. We hope to continue collecting data on the therapeutic effects of the device as we continue to work with health care providers in detecting and alleviating the aforementioned health concerns. 

In order to circumvent the ever-changing class of neuropsychiatric pathologies, we have created a neuromodulatory device that essentially massages this mind to relieve itself of unwarranted mental states and degenerative tendencies. The device is able to send multiple forms of electrical signals to target specific neural firing patterns. The user does not feel any initial sensations to the stimulation but the continual practice and usage of the device eventually helps rewire the brain to perform properly. In order to devise an optimal electrical stimulation, we use EEG channels to record the patient's ongoing mental states. We are also in the process of conducting fMRI studies to further our statistical analysis and therapeutic effects.

We have reported cases of patients who have reported a significant increase in overall health as devices served to mitigate their symptoms. Parkinson's patients have seen a decrease in tremors and apathetic patients have reported positive increases in mood. 

We believe our mission and focus go hand and hand with the horizon challenge. Our primary goal is to improve patient outcomes by fostering collaboration among patients, scientists, and health care providers. In order to improve the treatment of neuropsychiatric disorders, we utilize data analytic approaches as we strive to create a self-referencing protocol that is able to instill a connection amongst patients who feel helpless from their ailment.

We are still at the prototype stage since we only have a functioning device. We are currently running trials on 50 individuals to mitigate dementia and Alzheimers.  We are currently trying to transition into the growth face in order to run more trials while increasing the patient population in which we deploy the various pulse protocols. 

It's has been more than ten years since the constructive effects of electric stimulation on neuronal networks have drawn the attention of neuroscientists. One of the applied non-invasive approaches is noninvasive Trans-cranial Direct Current Stimulation (TDCS). This is a powerful FDA which is proved to be effective in the reconstruction of neuronal networks. This approach applies low-current non-invasive direct electrical stimulation. Although this approach is a powerful means for network reconstruction, there is still room for enhancement for increase in the efficacy of the treatment.

At U the Brain company, we have created a  device that modulates the patient's dysfunctional neural oscillations to replicate that of a healthy brain. In order to do so, we use the cutting-edge technology known as tPCS. tPCS is an existing technology similar to the well-known transcranial direct current stimulation (tDCS).  tDCS uses channel electrodes to send a low app current directly to the brain. When anodal tDCS (positive charge) is used, the electrode is able to depolarize the proximal cells within the region of interest. When cathodal tDCS (positive charge) is used, the electrode is able to hyperpolarize the target area. tPCS uses the same approach as tDCS but instead of applying a constant direct current, tPCS applies a unidirectional flow of positive or negative pulses. The pulse duration and interpulse duration is designed in a degree that optimizes to a desirable modulatory effect for the patient.

https://journals.sagepub.com/d...https://journals.plos.org/plos...

tPCS has been shown to have modulatory effects on corticospinal excitability. tPCS has also been shown to improve Gait and Balance in Parkinsonian patients. To further implement these protocols we use a closed-loop system that essentially reads the subject's brain waves (via EEG) and creates an optimal stimulatory pattern that may serve to alleviate the patient of his or her neurological ailment. 

 I have attached the following articles that demonstrate these findings. 

The device applies Trans-cranial Pulsed Current Stimulation (TPCS) to the brain and causes neuronal networks' reconstruction. As a synchronizer of neurons' firing(external pulse maker, kinda!), it helps the neurons fire and sets a new signaling pattern beside the pattern which already is in process. This makes injured patterns that are "off", "on" again, and "on" networks work harder. This may cause headaches, agitations, feelings of signal in the spinal cord, etc. This means that this approach should be personalized. Each person should receive appropriate signal induction due to his/her brain state. The "brain state" means the degree that a person's neuronal network is active. One particular electric signal may result in network renewal and get it "on" again and make another network interrupted. By personalizing devices using brain states, we will be able to provide appropriate signals. We have seen (experimentally, not published) that when we coordinate the signal with network activity, the agitations reduce and the problems get fixed to a good degree.

We have over 50 individuals suffering from a variety of disorders using our new transcranial pulsed current technology. In one year, we will have over 80 individuals due to our n=30 fMRI trial for Dementia of the Alzheimer's type over the course of 12 weeks. After this, we will focus our efforts to raise funding to then run a Phase 3 trial of n=150 for Dementia of The Alzheimer’s type. At that moment in time, we will work alongside the FDA for Device approval on a Class II designation. We expect to get FDA Approval for Dementia of The Alzheimer’s type within 5 years and thus be able to serve the 6.2 million Americans in the United States who suffer from Dementia.

Our goals for the next year are to complete the n=30 fMRI trial for Dementia of the Alzheimer’s type, continue case study investigations of tPCS in Parkinson’s Disease, and start a pilot IRB study using tPCS in Multiple Sclerosis and its classes. We submitted an IRB request to Shiraz University in Tehran, Iran to initiate the Dementia Trial and we are connecting and collaborating with local physicians in the United States to further our investigations into other neurodegenerative disorders. Over time, as we collect more quantitative data points, we will broaden our network and potential to raise large-scale funding to initiate trials with different endpoints. Our goals will be achieved by consistency, patience, and strategic decision making when raising funding to be allocated towards different Clinical Trials.

We have two types of ways to measure progress: quantitative and qualitative. Quantitatively, we are measuring our impact analysis with clinical trials, device manufacturing timeline, and marketing awareness. We have standard Good Clinical Practice Procedures with all our Clinical Trials to ensure robust data collection, patient data safety, and proper reporting of all data and adverse events to the correct regulatory board. This standard method will ensure all Clinical Trial practices will have integrity in the eyes of the FDA and international medical regulatory agencies. Furthermore, we are aligning our trials to collect quantitative biomarkers that elucidate the mechanisms of actions of our new pulse technology. This way, we can set up IRB research studies (without clinical investigations) to run more complex analyses from neuroimaging markers to refine the technology on a deeper mechanistic level.

The qualitative data will come from the subjective reports from device use in regard to devices' subjective effects on conscience, device quality and comfort, and other functional variables such as portability, miscellaneous improvements, and design aesthetics. This data is very important for U to expand into the consumer wellness market in the future as well as improve incrementally on our medical technologies to maximize device comfort, experience, and design.

Mohammed Abouelsoud, Dr.Jeffrey Spitzner PhD, Dr. Mohan Muvvala DO, and Dr. Sam Khozin MD are key executives at U: The Mind Company. Our expertise includes neuroengineering, regulatory expertise, functional medicine specialist, and physician entrepreneurship. Along with medical school and undergraduate students. We have a total of 9 full-time team members. 

Our goal is to train the lower layers of an organization to lead like the higher layers as well as allow the higher layers to share responsibilities with lower layers. We train each member coming into the company to be a leader. This way the company becomes flat, and everyone is at their own center. We hire the greatest minds on the planet to create the greatest leaders on the planet. 

Furthermore, we have a team of bright, young, professional undergraduates from many top Universities in the North American region including The Ohio State University, University of Pennsylvania, Cornell University, and University of Toronto.

Our approach to building a diverse team is based on the idea of Expansion-Centralization. Traditionally, companies are built to be top-down or bottom-up. 

Top-down company structuring works on the highest level of the organization, the executives, and work downward onto lower layers of the company, the employees. This saves time, reduces decision error, establishes precise deadlines, and maintains organizations on tasks. However, this could lead to low employee morale, reduced flexibility on project creativity, and reduced self-awareness in lower layers of the organization.  In a bottom-up company, lower levels of a company greatly influence the overall direction of an organization in the top layers of the organization. This layers empowers employees, increases creativity and collaboration in projects, agility and flexibility in information flow, and reduces pressures on upper-company-layers. The downside, budgeting on projects may not be aligned with corporate objectives, less organization in project execution, an extended timelines and costs due to mis-direction in tasks. At U, we combine the qualities of both approaches to create a new system of leadership: Expansion-Centralization. Our goal is to train the lower layers of an organization to lead like the higher layers as well as allow the higher layers to share responsibilities with lower layers. We train each member coming into the company to be a leader. This way the company becomes flat, and everyone is at their own center. We hire the greatest minds on the planet to create the greatest leaders on the planet. 

no

The Horizon Prize seems to be well set up and structured which gives us the impression that the partnerships, network, and resources will mirror this. There are many ‘competitions’ or ‘incubators’ that are not well poised to scale their applicants; the horizon prize has a good tracking record of helping others.

We mostly need partnership with researchers and physicians to be able to carry out studies alongside us to get more quantitative data points for tPCS. We want to do this in the short term and in the long term. Furthermore, we are looking for hardware and software engineers to aid us in the development of the final device and packaging of the device. We enjoy working with great minds to great bright leaders on the team. Building a solid team foundation early will help us for the many years ahead.

We would love to partner with organizations that lead the same principles as ours: to serve, to lead, and to heal. We want to partner with labs and hospitals to write STTR/SBIR grants with them as well as run joint IRB studies to further investigations into this new technology. Furthermore, we want to partner with community Nonprofits to aid with social causes even outside of medicine.